@article { ISI:000333747600004,
	title = {Fluorinated Mechanism-Based Inhibitors: Common Themes and Recent Developments},
	journal = {CURRENT TOPICS IN MEDICINAL CHEMISTRY},
	volume = {14},
	number = {7},
	year = {2014},
	month = {APR},
	pages = {865-874},
	abstract = {Mechanism-based inhibitors are relatively chemically inert compounds that become activated when processed by their target enzyme, leading to covalent enzyme inactivation. Fluorine substitution confers a number of properties that are beneficial to the chemistry of such inhibitors and to their potential use as pharmaceuticals, and indeed several fluorinated mechanism-based inhibitors have made it to clinical usage over the past 50 years. Well-known examples are the 5-fluorouracil metabolite, 5-fluoro-2{\textquoteright}-deoxyuridine-5{\textquoteright}-monophosphate, which is used in the treatment of cancer, and alpha-difluoromethylornithine for the treatment of African sleeping sickness. As the prevalence of fluorine in medicinal chemistry continues to rise, more and more medically relevant fluorinated mechanism-based inhibitors are being developed with a variety of interesting properties and uses.},
	issn = {1568-0266},
	author = {Tysoe, Christina and Withers, Stephen G.}
}
